Biotech firm shows the way onto the global stage
InvitroCue debuts on the ASX just four years after its birth; sales growth has doubled and is 'sustainable', says founder
Singapore
SUCCESS stories in the Singapore life sciences sphere are few and far between, but InvitroCue, which targets profitability in seven years, could light the way for other homegrown biotechnology firms seeking to get on the global stage.
The biotech firm, a spin-off from the Agency for Science, Technology and Research (A*Star), helps drug-makers determine which vaccines, products or devices are safe to use in humans - even before tests are conducted to determine if they work.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
US bill to restrict WuXi AppTec, Chinese biotechs revised to give more time to cut ties
Barclays cuts jobs in energy transition team it only just built
UMS Holdings Q1 net profit drops 44% to S$9.8 million
SIA Engineering H2 profit rises 11.5% to S$37.8 million on robust aviation MRO demand
Great Eastern shares jump 39% as OCBC mounts S$1.4 billion privatisation bid at S$25.60 per share
US: Wall St opens higher, focus on comments from Fed officials